Do analysts recommend FBLG or CYCN?

FibroBiologics presently has a consensus price target of $73.00, indicating a potential upside of 8,780.78%. Given FibroBiologics' stronger consensus rating and higher probable upside, equities research analysts clearly believe FibroBiologics is more favorable than Cyclerion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to FBLG or CYCN?

In the previous week, FibroBiologics had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 3 mentions for FibroBiologics and 2 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.50 beat FibroBiologics' score of 1.00 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cyclerion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer FBLG or NAII?

FibroBiologics currently has a consensus price target of $73.00, suggesting a potential upside of 8,780.78%. Given FibroBiologics' stronger consensus rating and higher probable upside, research analysts clearly believe FibroBiologics is more favorable than Natural Alternatives International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, PASG or FBLG?

Passage Bio is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A FibroBiologics N/A N/A -$18.65M -$5.19 N/A

Is PASG or FBLG more profitable?

Passage Bio's return on equity of -150.88% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% FibroBiologics N/A -536.78% -225.12%

Does the media favor PASG or FBLG?

In the previous week, FibroBiologics had 1 more articles in the media than Passage Bio. MarketBeat recorded 3 mentions for FibroBiologics and 2 mentions for Passage Bio. FibroBiologics' average media sentiment score of 1.00 beat Passage Bio's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FibroBiologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer FBLG or GTBP?

FibroBiologics currently has a consensus target price of $73.00, indicating a potential upside of 8,780.78%. Given FibroBiologics' stronger consensus rating and higher probable upside, equities analysts plainly believe FibroBiologics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, FBLG or GTBP?

FibroBiologics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FibroBiologics N/A N/A -$18.65M -$5.19 N/A GT Biopharma N/A N/A -$28.35M -$6.33 N/A

Is FBLG or GTBP more profitable?

GT Biopharma's return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -536.78% -225.12% GT Biopharma N/A N/A -102.03%

Do analysts prefer BFRI or FBLG?

FibroBiologics has a consensus target price of $73.00, indicating a potential upside of 8,780.78%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 FibroBiologics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80

FibroBiologics (FBLG) Competitors

$0.82 +0.03 (+3.98%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$0.82 -0.01 (-0.73%)

As of 08/4/2026 07:38 PM Eastern

Compare

FBLG vs. CYCN, NAII, PASG, GTBP, and BFRI

Should you buy FibroBiologics stock or one of its competitors? MarketBeat compares FibroBiologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FibroBiologics include Cyclerion Therapeutics (CYCN), Natural Alternatives International (NAII), Passage Bio (PASG), GT Biopharma (GTBP), and Biofrontera (BFRI).

How does FibroBiologics compare to Cyclerion Therapeutics?

FibroBiologics (NASDAQ:FBLG) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

In the previous week, FibroBiologics had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 3 mentions for FibroBiologics and 2 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.50 beat FibroBiologics' score of 1.00 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cyclerion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

FibroBiologics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

FibroBiologics presently has a consensus price target of $73.00, indicating a potential upside of 8,780.78%. Given FibroBiologics' stronger consensus rating and higher probable upside, equities research analysts clearly believe FibroBiologics is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 9.3% of FibroBiologics shares are owned by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cyclerion Therapeutics has higher revenue and earnings than FibroBiologics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A
Cyclerion Therapeutics	$2.07M	7.94	-$3.53M	-$1.36	N/A

FibroBiologics has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -62.10% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-536.78%	-225.12%
Cyclerion Therapeutics	-170.11%	-62.10%	-55.14%

Summary

Cyclerion Therapeutics beats FibroBiologics on 9 of the 15 factors compared between the two stocks.

How does FibroBiologics compare to Natural Alternatives International?

FibroBiologics (NASDAQ:FBLG) and Natural Alternatives International (NASDAQ:NAII) are related small-cap companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

32.4% of Natural Alternatives International shares are held by institutional investors. 9.3% of FibroBiologics shares are held by company insiders. Comparatively, 20.8% of Natural Alternatives International shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

FibroBiologics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

FibroBiologics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-536.78%	-225.12%
Natural Alternatives International	-10.13%	-12.21%	-5.30%

In the previous week, FibroBiologics had 3 more articles in the media than Natural Alternatives International. MarketBeat recorded 3 mentions for FibroBiologics and 0 mentions for Natural Alternatives International. FibroBiologics' average media sentiment score of 1.00 beat Natural Alternatives International's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the media.

Company	Overall Sentiment
FibroBiologics	Positive
Natural Alternatives International	Neutral

Natural Alternatives International has higher revenue and earnings than FibroBiologics. Natural Alternatives International is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A
Natural Alternatives International	$129.86M	0.11	-$13.57M	-$2.39	N/A

FibroBiologics currently has a consensus price target of $73.00, suggesting a potential upside of 8,780.78%. Given FibroBiologics' stronger consensus rating and higher probable upside, research analysts clearly believe FibroBiologics is more favorable than Natural Alternatives International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

FibroBiologics beats Natural Alternatives International on 8 of the 15 factors compared between the two stocks.

How does FibroBiologics compare to Passage Bio?

Passage Bio (NASDAQ:PASG) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Passage Bio's return on equity of -150.88% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
FibroBiologics	N/A	-536.78%	-225.12%

In the previous week, FibroBiologics had 1 more articles in the media than Passage Bio. MarketBeat recorded 3 mentions for FibroBiologics and 2 mentions for Passage Bio. FibroBiologics' average media sentiment score of 1.00 beat Passage Bio's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Passage Bio is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

Passage Bio presently has a consensus price target of $13.25, suggesting a potential upside of 186.18%. FibroBiologics has a consensus price target of $73.00, suggesting a potential upside of 8,780.78%. Given FibroBiologics' higher possible upside, analysts plainly believe FibroBiologics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Passage Bio has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

53.5% of Passage Bio shares are held by institutional investors. 4.9% of Passage Bio shares are held by insiders. Comparatively, 9.3% of FibroBiologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

FibroBiologics beats Passage Bio on 7 of the 13 factors compared between the two stocks.

How does FibroBiologics compare to GT Biopharma?

FibroBiologics (NASDAQ:FBLG) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

In the previous week, FibroBiologics had 3 more articles in the media than GT Biopharma. MarketBeat recorded 3 mentions for FibroBiologics and 0 mentions for GT Biopharma. FibroBiologics' average media sentiment score of 1.00 beat GT Biopharma's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the media.

Company	Overall Sentiment
FibroBiologics	Positive
GT Biopharma	Neutral

GT Biopharma's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-536.78%	-225.12%
GT Biopharma	N/A	N/A	-102.03%

FibroBiologics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

FibroBiologics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

FibroBiologics currently has a consensus target price of $73.00, indicating a potential upside of 8,780.78%. Given FibroBiologics' stronger consensus rating and higher probable upside, equities analysts plainly believe FibroBiologics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.2% of GT Biopharma shares are held by institutional investors. 9.3% of FibroBiologics shares are held by insiders. Comparatively, 1.2% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

FibroBiologics beats GT Biopharma on 9 of the 13 factors compared between the two stocks.

How does FibroBiologics compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, FibroBiologics had 3 more articles in the media than Biofrontera. MarketBeat recorded 3 mentions for FibroBiologics and 0 mentions for Biofrontera. FibroBiologics' average media sentiment score of 1.00 beat Biofrontera's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biofrontera	Neutral
FibroBiologics	Positive

10.1% of Biofrontera shares are held by institutional investors. 8.1% of Biofrontera shares are held by insiders. Comparatively, 9.3% of FibroBiologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Biofrontera has higher revenue and earnings than FibroBiologics. Biofrontera is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.37	-$10.54M	-$0.97	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

FibroBiologics has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Biofrontera's return on equity of -515.34% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
FibroBiologics	N/A	-536.78%	-225.12%

Biofrontera has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

FibroBiologics has a consensus target price of $73.00, indicating a potential upside of 8,780.78%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

FibroBiologics beats Biofrontera on 8 of the 14 factors compared between the two stocks.

Get FibroBiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBLG vs. The Competition

Export

Metric	FibroBiologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.26M	$3.52B	$6.83B	$12.76B
Dividend Yield	N/A	3.77%	2.59%	10.01%
P/E Ratio	-0.16	7.32	279.15	25.53
Price / Sales	N/A	1,269.95	592.00	94.29
Price / Cash	N/A	103.44	72.11	49.39
Price / Book	1.17	17.07	12.95	6.11
Net Income	-$18.65M	-$12.52M	$3.48B	$347.58M
7 Day Performance	25.57%	3.66%	3.40%	4.91%
1 Month Performance	-6.11%	-5.36%	-2.79%	-2.06%
1 Year Performance	-92.60%	49.41%	73.07%	21.03%

FibroBiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBLG FibroBiologics	2.8921 of 5 stars	$0.82 +4.0%	$73.00 +8,780.8%	-93.2%	$5.26M	N/A	N/A	10	News Coverage Earnings Report Analyst Downgrade Gap Down
CYCN Cyclerion Therapeutics	1.5358 of 5 stars	$3.55 +1.3%	N/A	+26.0%	$15.35M	$1.99M	N/A	30	Positive News Earnings Report
NAII Natural Alternatives International	0.4971 of 5 stars	$2.36 -0.5%	N/A	-37.5%	$14.82M	$129.86M	N/A	290	Positive News Gap Up
PASG Passage Bio	3.2314 of 5 stars	$4.51 -2.3%	$13.25 +193.6%	-19.3%	$14.47M	N/A	N/A	130	News Coverage
GTBP GT Biopharma	0.103 of 5 stars	$0.32 -5.7%	N/A	-81.7%	$14.19M	N/A	N/A	8

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBLG) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FibroBiologics (FBLG) Competitors

FBLG vs. CYCN, NAII, PASG, GTBP, and BFRI

How does FibroBiologics compare to Cyclerion Therapeutics?

Summary

How does FibroBiologics compare to Natural Alternatives International?

Summary

How does FibroBiologics compare to Passage Bio?

Summary

How does FibroBiologics compare to GT Biopharma?

Summary

How does FibroBiologics compare to Biofrontera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FibroBiologics (FBLG) Competitors

FBLG vs. CYCN, NAII, PASG, GTBP, and BFRI

How does FibroBiologics compare to Cyclerion Therapeutics?

Does the media refer more to FBLG or CYCN?

Which has more volatility & risk, FBLG or CYCN?

Do analysts recommend FBLG or CYCN?

Do insiders and institutionals believe in FBLG or CYCN?

Which has better valuation & earnings, FBLG or CYCN?

Is FBLG or CYCN more profitable?

Summary

How does FibroBiologics compare to Natural Alternatives International?

Do insiders & institutionals hold more shares of FBLG or NAII?

Which has more volatility and risk, FBLG or NAII?

Is FBLG or NAII more profitable?

Does the media prefer FBLG or NAII?

Which has preferable valuation & earnings, FBLG or NAII?

Do analysts prefer FBLG or NAII?

Summary

How does FibroBiologics compare to Passage Bio?

Is PASG or FBLG more profitable?

Does the media favor PASG or FBLG?

Which has stronger valuation & earnings, PASG or FBLG?

Do analysts recommend PASG or FBLG?

Which has more risk and volatility, PASG or FBLG?

Do institutionals and insiders have more ownership in PASG or FBLG?

Summary

How does FibroBiologics compare to GT Biopharma?

Does the media refer more to FBLG or GTBP?

Is FBLG or GTBP more profitable?

Which has higher valuation and earnings, FBLG or GTBP?

Which has more risk and volatility, FBLG or GTBP?

Do analysts prefer FBLG or GTBP?

Do institutionals & insiders believe in FBLG or GTBP?

Summary

How does FibroBiologics compare to Biofrontera?

Does the media prefer BFRI or FBLG?

Do institutionals & insiders believe in BFRI or FBLG?

Which has better valuation & earnings, BFRI or FBLG?

Is BFRI or FBLG more profitable?

Which has more volatility & risk, BFRI or FBLG?

Do analysts prefer BFRI or FBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools